Prescribing InformationFor Patients

The safety of XERMELO + SSA was comparable to that of SSA alone

Adding XERMELO to SSA therapy delivers a safety profile comparable to that of SSA alone. Plus, there are no contraindications to giving XERMELO with other tumor-directed therapies such as PRRT or chemoembolization.1

The incidence* of adverse events was similar among patients treated with XERMELO + SSA and those treated with SSA alone.1

Adverse reaction*XERMELO 250 mg + SSA
(n=45)
SSA alone
(n=45)
Nausea13%11%
Headache11%4%
Gamma-glutamyl-transferase increased9%0%
Depression
Including depression, depressed mood, and decreased interest
9%7%
Edema peripheral7%2%
Flatulence7%2%
Decreased appetite7%4%
Pyrexia7%4%
 *Incidence of ≥5% in the XERMELO treatment group and at an incidence greater than SSA alone.

XERMELO + SSA combination therapy resulted in lower discontinuation rates2

Treatment-emergent discontinuation rates were low across all treatment groups.

What your patients need to know1

Take XERMELO 250 mg 3 times daily to reduce carcinoid syndrome diarrhea
Take XERMELO with food to aid in absorption
It may take 12 weeks to respond to treatment with XERMELO + SSA

How to Order XERMELO

3 Ways to Prescribe XERMELO
  • LexCares Enrollment Form
  • Direct through Specialty Pharmacy (Diplomat or Biologics)
  • EHR
3 Items Required to Prescribe XERMELO
  • Prescription (Rx)
  • Patient's Insurance Rx/PA
  • Patient's Clinical Notes (to support Rx/PA process)

Get your patient started on XERMELO.

References:

1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February 2017.2. Kulke MH, Hörsch D, Caplin ME, et al. J Clin Oncol. 2017;35:14-23.

You may report an adverse event related to Lexicon products by calling 1-844-LEX-PHAR (1-844-539-7427) (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.

Copyright © 2019 Lexicon Pharmaceuticals, Inc. All rights reserved.
December 2019 PP-XER-US-0053

Important Safety Information and Indication

Important Safety Information

For more information about XERMELO see Full Prescribing Information

  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: The most common adverse reactions (≥5%) include nausea, headache, increased gammaglutamyl-transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.

Indication

  • XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

For more information about XERMELO see Full Prescribing Information